Clorox Pre-Q4 Earnings Send Mixed Signals: Time to Accumulate Shares?

Clorox (CLX) is expected to post Q4 fiscal 2025 revenue of $1.94 billion, up 2% year-over-year, and EPS of $2.25, a 23.6% increase, attributed to its IGNITE strategy, premium innovation, and cost discipline supporting a projected 44% gross margin. Despite these internal strengths, the company navigates a challenging macroeconomic environment, increased advertising spend, stiff competition, and elevated SG&A from digital and ERP investments. Zacks' model, however, issues a 'Strong Sell' rating with a negative Earnings ESP, and CLX stock has significantly underperformed its industry year-to-date, despite trading at a slight valuation discount.

Analysis

The Clorox Company (CLX) presents a mixed outlook ahead of its fiscal fourth-quarter 2025 earnings report. Consensus estimates project strong bottom-line performance, with EPS expected to grow 23.6% year-over-year to $2.25, while revenue is anticipated to increase a modest 2% to $1.94 billion. This expected profitability is underpinned by the company's IGNITE strategy, successful premium product launches, and disciplined cost management, which have contributed to ten consecutive quarters of gross margin growth. For Q4, gross margin is projected at 44%, and adjusted operating profit is modeled to increase 27% with a 400 basis point margin expansion to 20.2%. A temporary sales uplift may also materialize from retailer inventory builds ahead of an ERP system transition. However, these operational strengths are countered by significant headwinds. The company faces a challenging consumer environment, stiff competition, and rising costs associated with advertising, tariffs, and SG&A from its ERP investment. Critically, the stock has severely underperformed, falling 21.6% year-to-date, in stark contrast to its industry's 2.4% decline. Despite trading at a slight valuation discount with a forward P/E of 19.50x, quantitative models are highly bearish, with a Zacks Rank of 5 (Strong Sell) and a negative Earnings ESP of -3.62%, indicating that an earnings beat is not predicted.

Key Decisions for Investors

• Given the Zacks 'Strong Sell' rating, negative Earnings ESP, and significant stock underperformance, investors should exercise extreme caution, as these indicators suggest a high probability of a negative earnings surprise or disappointing forward guidance.
• Focus on the actual gross margin figure to validate if the projected 44% is achieved, as continued margin expansion is the core tenet of the bull thesis against a backdrop of weak full-year revenue forecasts.
• Despite the stock trading at a valuation discount to its peers, the severe negative momentum and bearish quantitative signals suggest that accumulating shares ahead of the report carries substantial risk.